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Objective: To evaluate safety, tolerability and feasibility of long-term treatment with
Granulocyte-colony stimulating factor (G-CSF), a well-known hematopoietic stem cell
factor, guided by assessment of mobilized bonemarrow derived stem cells and cytokines
in the serum of patients with amyotrophic lateral sclerosis (ALS) treated on a named
patient basis.
Methods: 36 ALS patients were treated with subcutaneous injections of G-CSF on
a named patient basis and in an outpatient setting. Drug was dosed by individual
application schemes (mean 464 Mio IU/month, range 90-2160 Mio IU/month) over a
median of 13.7 months (range from 2.7 to 73.8 months). Safety, tolerability, survival
and change in ALSFRS-R were observed. Hematopoietic stem cells were monitored by
flow cytometry analysis of circulating CD34+ and CD34+CD38− cells, and peripheral
cytokines were assessed by electrochemoluminescence throughout the intervention
period. Analysis of immunological and hematological markers was conducted.
Results: Long term and individually adapted treatment with G-CSF was well tolerated
and safe. G-CSF led to a significant mobilization of hematopoietic stem cells into the
peripheral blood. Higher mobilization capacity was associated with prolonged survival.
Initial levels of serum cytokines, such as MDC, TNF-beta, IL-7, IL-16, and Tie-2 were
significantly associated with survival. Continued application of G-CSF led to persistent
alterations in serum cytokines and ongoing measurements revealed the multifaceted
effects of G-CSF.
Conclusions: G-CSF treatment is feasible and safe for ALS patients. It may exert its
beneficial effects through neuroprotective and -regenerative activities, mobilization of
hematopoietic stem cells and regulation of pro- and anti-inflammatory cytokines as well
as angiogenic factors. These cytokinesmay serve as prognostic markers whenmeasured
at the time of diagnosis. Hematopoietic stem cell numbers and cytokine levels are altered
by ongoing G-CSF application and may potentially serve as treatment biomarkers for
early monitoring of G-CSF treatment efficacy in ALS in future clinical trials.
Keywords: amyotrophic lateral sclerosis, granulocyte-colony stimulating factor, cytokines, hematopoietic stem
and progenitor cells, HSPC, treatment
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a life threatening
neurodegenerative disorder characterized by premature loss of
upper and lower motoneurons in the adult brain and spinal cord
(1). The life time risk of ALS is below one in 400 individuals
(2), the incidence is 2–3 per 100,000 in Europe (3). The unmet
medical need in ALS patients is underlined by a median survival
of 29.8 months from symptom onset, and of 15.8 months from
diagnosis (4). Only modest treatment effects have been observed
by riluzole (5) and edaravone (6).
In view of the great heterogeneity of disease etiology,
neuronal damage likely results from many different pathologic
changes, including neuroinflammation (3). Neurodegenerative
processes with altered homeostasis, protein accumulation and
cell death generates neuroinflammation, and central nervous
system (CNS)-resident immune cells such as astrocytes and
microglia trigger neuroinflammation and neurodegeneration (7).
Inflammation may arise reactive to ALS-related CNS alterations,
but also play an initial role and trigger both onset of disease and
further accelerate progression of ALS (3). A complex, cytokine-
mediated crosstalk between CNS and systemic immune cells
regulates immune responses to either pro- or anti-inflammatory
states, which evolve over time (7).
Granulocyte-colony stimulating factor (G-CSF) is a 20-kDa
glycoprotein and a well characterized growth factor that plays
a key role in production, mobilization, and differentiation of
hematopoietic stem cells (8, 9). It is a widely used compound
for treatment of neutropenia and for mobilization of CD34+
hematopoietic stem cells prior to bone marrow transplantation.
G-CSF enhances immunocompetence and has systemic anti-
inflammatory effects (10). G-CSF is safe and well tolerated; most
common side effects aremoderate bone pain andmusculoskeletal
pain in 20–30% of patients, rarely splenomegaly and allergic
reactions (11). Aside from hematopoietic functions, G-CSF
acts as a neuronal growth factor in the CNS and possesses
neuroprotective and -regenerative properties (12, 13). G-CSF
passes the intact blood brain barrier, and its receptor is widely
expressed within the CNS (12). G-CSF is thought to be
neuroprotective through anti-apoptotic effects (12, 14), it induces
neural differentiation, supports neurogenesis, contributes to re-
endothelialization and arteriogenesis (12, 15). Systemic G-CSF
induced hematopoietic stem cells may contribute on a direct
cellular level in neurodegeneration by migration to the CNS
(16, 17), where they may offer trophic support and modulate
the local CNS immune system (17, 18). Observing G-CSF
induced systemic hematopoietic stem cells may also shed light
upon direct G-CSF effects on neural cells and stem cells as
a surrogate system. Furthermore, G-CSF modulates monocyte
function and attenuates the neuroinflammatory cascade (13).
An interesting bone marrow-brain connection has been shown
as G-CSF induced bone marrow derived cells migrate to
CNS and express microglial phenotype in a mouse model of
cranial irradiation. This was associated with a better functional
outcome and suggested to facilitate neuroprotection by direct
effects on resident CNS cells as well as modulation of cellular
microenvironment in neurovascular niches (15). Angiogenic
factors may promote neurogenesis through direct effects on
neuronal cells (19) and indirectly by angiogenic support of
the highly vascularized neurogenic zones. G-CSF improved
motor function and survival in mouse models of ALS (20–
22). Small trials with G-CSF treatment in ALS patients
demonstrated excellent tolerability and safety (23–25), with
modulation of immune parameters (26), and possible minor
benefits detected by neuroimaging (27). In summary, G-CSF
exerts multiple physiological effects within the CNS and may
be a potent modulator of different functions relevant to ALS
pathophysiology (13). Importantly, from in vitro, mouse model
and human exploratory evidence the mode of action most
relevant for potential treatment effects cannot with certainty be
concluded.
Due to the paucity of available treatment options we provided
individual, off-label G-CSF treatment to ALS patients. G-CSF,
considering its multimodal systemic and CNS effects, may be
a promising treatment option in view of the etiopathological
and clinical heterogeneity of ALS. Biomarkers are measurable
indicators of disease and/or intervention and may be useful
in monitoring long-term degenerative or reparative processes
within the CNS. In view of the above-discussed complexity of
ALS, it seems unlikely that a single biomarker can sufficiently
reflect treatment effects on disease progression. We therefore
used a panel of pro- and anti-inflammatory blood parameters,
angiogenic factors, as well as hematopoietic stem cell markers.
Monitoring pro-differentiation and -mobilization effects on
hematopoietic stem cells may serve as a proxy for G-CSF activity
on neural stem cells in individual patients and/or reflect direct
and indirect beneficial effects of mobilized hematopoietic stem
cells. Observing a panel of peripheral cytokinesmay reveal system
wide immune and inflammatory status relevant for peripheral-
CNS crosstalk.
G-CSF is known to be a safe stem-cell mobilizing agent. We
investigated whether the number of mobilized hematopoietic
stem cells is different in G-CSF treated ALS patients of longer
versus shorter survival. Secondly, we were interested in whether
baseline cytokine levels are associated with survival of G-CSF
treated ALS patients. Lastly, we sought to explore hematopoietic
stem cells and cytokine level alterations during G-CSF treatment.
METHODS
Patients, Procedures and Ethics
Treatment with G-CSF was offered to 36 patients seen at
the University of Regensburg with definite or probable ALS
according to the revised El Escorial criteria (28). As this was not
a prospective clinical trial, the use of formal exclusion criteria
was not considered appropriate. However, neither patients with a
current or past history of neurologic disease other than ALS, nor
patients participating in any interventional study were offered
this treatment option. Individual treatment of ALS patients
and retrospective evaluation was done after written informed
consent. The ethics committee of the University of Regensburg
approved a retrospective analysis (ethics approval: 15-101-0106
and 14-101-0011). The principles of the Declaration of Helsinki
(World Medical Association, revised version 2013) were strictly
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adhered to. Survival was defined as the time between diagnosis
and death from confirmed ALS-related complications, including
suicide.
ALS patients were treated with subcutaneous injections of
recombinant human G-CSF (Filgrastim) on an outpatient basis.
Dose and application modes were adapted individually upon
initiation and over time (Figure 1; Table S1). Adaption was
made with the intent to maximize patient wellbeing and safety
in the presence of any emerging safety signals, and with the
aim of increasing efficacy as monitored by levels of mobilized
hematopoietic stem cells, a potential individual marker of
biological activity of G-CSF. This resulted in heterogeneous
treatment schemes. The intervention and evaluation was initiated
in January 2010 and is still ongoing. The data were analyzed up to
March 2017. The treatment was provided by the hospital and not
funded by a pharmacological company or other external source.
No external or internal funding sources were involved in patient
selection, study design, data analysis or interpretation.
Patient safety was analyzed at baseline (initiation of treatment)
followed by monthly control visits with clinical examinations,
blood counts, cytokines, blood smears and estimation of bone
marrow function. We conducted baseline spleen sonography
with follow-ups upon dose escalation. Clinical ALS progression
was monitored using the established ALSFRS-R (29). If patients
were not able to continue visits and treatment, patient survival
was monitored by phone calls to patients, their families and
general practitioners.
Changes in pro- and anti-inflammatory immune profiles were
evaluated at baseline, at 3 months, and then every 6 months
throughout treatment by multiplex electrochemoluminescence
with the panel assay V-PLEX Human Biomarker 40-Plex
Kit (MesoScale Discovery R©, Maryland, USA). This industry
standard panel has been validated in different immune related
and non-immune diseases (manufacture’s information). In
patients receiving G-CSF on five consecutive days, evaluations
of cytokine levels in the peripheral blood were conducted twice
a month, before (day 0) and after G-CSF application (day 7).
FIGURE 1 | Treatment course. The monthly protocol is illustrated; this
schedule was repeated and individually adapted over the long-term treatment.
G-CSF was administered subcutaneously. Mainly, patients received G-CSF
either as a 5-day bolus (A) once (1st week) or twice (1st and 3rd week) or
continuously (B) on single days up to every second day; G-CSF was
administered in one or two doses á day. Blood was obtained before treatment
onset at baseline (d0) and then once á month (d0) in patients receiving G-CSF
continuously, and before (d0) as well as after a 5-day treatment (d7) in patients
on bolus application. Cytokines were analyzed at d0 in both groups and at d7
in bolus treatment in the first month (baseline), then at the 3rd and 6th month
during ongoing treatment.
In patients receiving G-CSF twice a week or every second
day, analyses were conducted on a monthly basis 1 day after
application. Peripheral blood serum was collected during regular
visits at the hospital and immediately stored at −20◦C for
cytokine assays. For each assay, 25µl of serum samples were used
and test carried out in duplicates, according to themanufacturer’s
instructions.
We analyzed white blood cells including cell differentiation,
platelet and red blood cell counts, and hemoglobin levels with
an automatic cell counter (Sysmex R©, Kobe, Japan). Peripheral
blood smears were done on a 3-month basis by light microscopy.
Peripheral blood CD34+ and CD34+CD38− hematopoietic stem
and progenitor cells (HSPC) were analyzed by flow cytometry
as earlier described by our group (25). In short, 1ml donor
blood was lysed in 9ml NH4Cl lysis buffer and cells were then
stained for 30min at 4◦C with combinations of anti-CD45-FITC
(clone HI30, BD Pharmingen, Franklin Lakes, NJ, USA), CD34-
APC (clone 581, Biolegend, San Diego, CA, USA) and CD38-PE
(clone HIT2, BioLegend) monoclonal antibodies. Analysis was
performed on a BectonDickinsonCALIBUR flow cytometer (BD,
East Rutherford, NJ, US).
Calculations and Statistics
Findings of immune parameters from three time points, baseline
(initiation of treatment), 3 months and 6 months were selected
for analysis. As patients did not always visit the outpatient clinic
on the exact days of the given time points, the time points had
to be defined as time periods. When assessing the ALSFRS-
R at baseline, data from day of treatment initiation ±28 days
were included. For baseline measures of blood counts, stem cell
mobilization parameters and cytokines, only data obtained before
the first G-CSF application were selected. The 3-month time
point was defined as day 45–134 and the 6-month time point as
ranging from day 135 to 224. If patients visited more than once
during these time periods, the day closest to the intended time
point was selected.
The immediate effects of G-CSF treatment on peripheral levels
of cytokines, hematopoietic stem cells and blood counts were
assessed by comparing respective levels 2 days before and 1 day
after a 5-day treatment course with G-CSF. We then explored
different patterns of immune responses depending on individual
survival. Survival time was defined as time elapsed from day of
diagnosis to day of death or day of last observation in the case of
censoring. For this purpose, G-CSF treated patients were divided
into two groups based on their survival being longer or shorter
than 30 months from diagnosis, as this was a time point that
separated the patients into two equal-sized groups. At the point of
database closure, patients who were still alive were censored and
included in the “long survival” group if they had been observed
for over 30 months (n = 7). Patients who were alive and had
not yet been observed for over 30 months were not considered
for this analysis (n = 3). The same censoring was applied for
correlation analysis. We then retrospectively analyzed baseline
levels of cytokines, hematopoietic stem cells and blood counts
in the long and short survivor groups and further correlated
survival with cytokines upon treatment initiation.
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R or GraphPad Prism 7 was employed for statistical analysis
and graph design. Correlations were analyzed using two-tailed
Pearson correlation and presented with correlation coefficient
(r), coefficient of determination (R2) and p-value. Comparisons
were made with Mann-Whitney test and paired Wilcoxon test.
Data were considered significant at p ≤ 0.05. A trend was noted
at p ≤ 0.1. Comparisons were corrected for multiple testing by
false discovery rate approach (FDR, two-stage step-up method of
Benjamin, Krieger and Yekutieli with desired FDR (Q) at 10%)
and considered a discovery at FDR-adjusted p-value (q) < 0.1.
We used an Area Under the Curve (AUC) approach to estimate
mobilization of hematopoietic stem cells after G-CSF treatment
over time. Stem cell measurements before and after G-CSF dosing
were available for patients on the 5-day treatment scheme. For
better comparability regarding long and short survival times after
diagnosis, we selected patients with ongoing 5-day treatment over
the first 4 months. All patient measurements were used in the
calculation. If patients had fewer data points, their mean AUC
value calculated from all data points was applied (in the case of
one patient). The AUC value was calculated with the auc function
of the R-package “flux” (Jurasinski, Koebsch, Guenther and Beetz,
2014). The baseline value at day 0 or from any day prior to
treatment start was used as threshold for the calculation.
RESULTS
Demographics, Intervention and Safety
36 caucasian ALS patients (25 male, 11 female, 28 limb onset, 8
bulbar onset, mean age 51.9 years, mean ALSFRS-R on initiation
38/48) were treated with G-CSF in addition to riluzole treatment.
We here report on individual treatment on a named patient
basis—consequently, treatment schemes were heterogeneous.
Dose and application modes were adapted individually upon
initiation and over time (Table S1). In summary, G-CSF was
injected subcutaneously in a dose-range from 90 to 2160 Mio
IU per month (900–21,600 µg/month), with a mean dose of
464Mio IU/month (4,640µg/month). Applicationmodes ranged
from once weekly to every second day in an ongoing individually
tailored manner. The median duration of treatment was 13.7
months (mean 16.7 months; range from 2.7 to 73.8 months)
(Table 1, Figure 1).
Long-term outpatient treatment with G-CSF was generally
well tolerated in ALS patients and compliance was excellent.
Minor adverse events were mild to moderate bone pain after
G-CSF injection and leukocytosis. One patient experienced an
episode with heat sensation, lightheadedness, and 15min. of
dyspnea on 1 day of drug application 39 months into G-CSF
treatment. Due to the possibility of drug-related intolerance or
mild allergic reaction, G-CSF was discontinued in this patient;
antibodies against G-CSF were not detectable. This patient was
switched from Filgrastim to Pegfilgrastim, a PEGylated form of
recombinant human G-CSF, from his 46th to 53rd month after
initiation, and then ended the off-label treatment without further
adverse reactions. As expected, mild to moderate splenomegaly
evolved during ongoing G-CSF treatment in most patients.
Without any further symptoms or complications, the mean
spleen width increased from 4.3 to 4.9 cm and length from
10.7 to 12.1 cm during treatment. There were no severe adverse
events (SAE), and no signs for pre-malignant transformation in
peripheral blood smears.
Baseline hematology showed no abnormalities in our patients.
G-CSF mobilizes neutrophil leukocytes as well as CD34+ and
CD34+CD38− hematopoietic stem and progenitor cells (HSPC)
from the bone marrow into the peripheral blood. Leukocyte
counts increased significantly in all treated patients, from an
initial mean of 6.9 × 103/µl to 48.2 × 103/µl (range 8.3–118.7
× 103/µl, p < 0.0001) after G-CSF application. A predicted
increase in the average percentage of neutrophils (from 64.8 to
87.3%, p < 0.0001) was accompanied by a relative decrease in
lymphocytes (from 24.1 to 7.0%, p < 0.0001), monocytes (from
8.8 to 4.7%, p < 0.0001) and eosinophils (from 1.8 to 0.7%, p
< 0.0001) as well as a small decrease in red blood cell count
(from 5.03 to 4.83× 103/µl, p< 0.0001), hemoglobin level (from
14.9 to 14.4 g/dl, p < 0.0001) and hematocrit (from 44.2 to 43.6,
p = 0.0362) during monitoring (all comparisons by paired t-
test, two-tailed p-value. Figure S1). There were no significant
changes in basophiles and platelet count during monitoring.
The fold increase of CD34+ and CD34+CD38− HSP cells in
peripheral blood served as an indicator of mobilization efficiency
and was determined by comparing cells at baseline to cells after
mobilization. The mobilization efficacy was heterogeneous with
high intra- and inter-personal variability (data not shown).
G-CSF-Mediated Stem Cell Mobilization
Was Associated With Survival of ALS
Patients
Twenty-six of thirty-six G-CSF treated patients deceased between
January 2010 and March 2017. 10 patients were alive, of which 6
were still treated with G-CSF. The patient who had suffered from
a possible allergic reaction was regularly seen at the clinic. Three
patients ended G-CSF treatment at days 82, 420 and 427, and
were all lost to follow up. The overall median survival of deceased
patients was 24.2 months from diagnosis (mean 25.5; range 3.9–
56.6 months). For further analysis, patients were divided into two
equally sized groups by survival being longer or shorter than 30
months from diagnosis. Patients, who were alive at the time of
database closure, were considered for this analysis had they been
observed for at least 30 months. The mean (median) survival
differed in the two survival groups: 46.59 (39.55) months, SD
16.34 and 17.04 (18.30) months, SD 8.16 (two-tailed p-value <
0.0001; Mann-Whitney t-test). The ALSFRS-R slope over time
was significantly flatter in longer surviving patients (Wilcoxon
test, p= 0.00086; Figure 2). Long survivors were younger (mean
age 46.8 vs. 56.5 y, unpaired t-test, p = 0.0163) and had a longer
latency between diagnosis and treatment onset (mean 333 vs.
163 days, unpaired t-test, p = 0.0377). Their clinical function
upon treatment initiation was not significantly different (mean
ALSFRS-R 38.6/48 vs. 37.3/48). Further, longer surviving patients
were less frequently female (18.8 vs. 47.1%), but had similar
occurrence of bulbar onset of disease (18.8 vs. 17.6%) (Table 1).
G-CSF is known to mobilize HSPC into the peripheral
circulation. CD34+ and CD34+CD38− HSPC were evaluated
in the sera of patients 2 days before (day 0) and 1 day after
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TABLE 1 | Demographics and intervention in G-CSF treated ALS patients.
ALS
patient
Age
(years)
Gender ALSFRS-R
baseline
Site of
onset
Time diagnosis to
treatment (days)
Dose G-CSF
(mean; range
(MioIE/month))
Treatment duration
(months)
Survival (months)
from diagnosis
1 50 F 38 Limb 498 150 (150–150) 19 36.2
2 42 M 32 Limb 619 280 (150–300) 31 52.2
3 77 M 21 Limb 759 173 (150–240) 5 33.4
4 68 F 39 Bulbar 29 150 (150–150) 3 3.9
5 67 M 33 Limb 439 260 (150–300) 20 56.6
6 26 M 33 Limb 486 485 (150–1170) 74 89.7*
7 50 F 33 Limb 536 240 (240–240) 7 25.4
8 73 M 41 Limb 270 166 (150–240) 11 21.4
9 50 M 28 Limb 393 133 (90–150) 7 21.4
10 56 M 37 Limb 770 242 (150–300) 14 40.0
11 41 M 38 Limb 24 287 (150–300) 27 36.3
12 35 F 40 Bulbar 115 296 (240–300) 14 63.7*
13 48 F 46 Limb 38 216 (150–300) 14 29.7
14 43 M 44 Limb 61 561 (192–768) 45 47.3
15 65 F 32 Limb 81 192 (192–192) 14 18.3
16 51 F 42 Limb 101 225 (150–300) 3 6.4
17 60 F 38 Limb 21 192 (192–192) 9 11.5
18 58 M 44 Limb 45 311 (240–480) 25 25.4
19 46 M 46 Limb 249 150 (150–150) 26 34.7
20 50 M - Limb 1 198 (192–240) 8 8.0
21 27 M 44 Limb 53 301 (150–600) 39 71.3*
22 45 M 48 Limb 26 666 (240–1296) 37 39.1*
23 55 M 40 Bulbar 26 263 (150–300) 3 41.9*
24 61 M 44 Limb 66 375 (150–510) 5 9.2
25 60 M 40 Bulbar 135 602 (240–816) 19 23.0
26 65 F 30 Bulbar 122 563 (240–900) 7 11.3
27 43 F 41 Limb 338 628 (240–720) 14 35.7*
28 60 M 42 Limb 23 589 (480–720) 11 12.1
29 45 F 28 Limb 493 535 (150–720) 6 29.6
30 47 M 29 Limb 396 585 (450–720) 5 19.3
31 50 M 40 Limb 23 667 (240–720) 8 13.7
32 39 M 41 Bulbar 343 1015
(450–1170)
20 31.7*
33 56 M 42 Bulbar 525 744 (450–1056) 11 35.6
34 59 M 38 Bulbar 52 1044
(450–1440)
14 #
35 69 M 39 Limb 62 1344
(450–2160)
16 #
36 35 M 38 Limb 288 1141
(300–1440)
14 #
Mean
(SD)
51.9
(12.2)
11 F
25M
38/48 (6.1) 28 Limb
8 Bulbar
236.3 (231.4) 222.7 (104.1) 16.7 (14.4) 25.5 (14.3)
in deceased
patients
Patients marked by # or * were alive upon closure of data admission. Patients who had been observed for less than 30 months at time of closure of data admission are marked by #.
The sign * indicates patients, who at time of closure of data admission, had been observed more than 30 months from diagnosis. Baseline ALSFRS-R was not available in one patient,
marked by -.
(day 7) a 5-day treatment course with G-CSF at baseline, 3
months and 6 months. G-CSF led to a sustained increase of
CD34+ and CD34+CD38− HSPC at all time points (Figure 3).
In patients treated with ongoing 5-day courses of G-CSF t-tests
displayed no significant reductions in mobilization of CD34+
and CD34+CD38− HSPC when comparing the respective levels
after G-CSF treatment at baseline and after 3 and 6 months
of treatment (mean number of CD34+/ml at baseline 30307,
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FIGURE 2 | ALSFRS-R decline is less rapid in patients who survive longer
than 30 months. Patients were assigned to high survival group at survival
longer or at 30 months, and to low survival group at survival below 30 months
from diagnosis. The slope was calculated by robust calculation of the
ALSFRS-R measurements. Median slope in the high survival group was
−0.019 and −0.05 in the low survival group. Wilcoxon test, p-value 0.00086.
at 3 months 35250, at 6 months 22017; mean number of
CD34+CD38−/ml at baseline 3092, at 3 months 2089, at
6 months 1632, all Wilcoxon paired t-test, all p-values not
significant; Figure S2). However, we found a different capacity
to mobilize hematopoietic stem cells in patients surviving
longer or shorter than 30 months from diagnosis. This was
analyzed by Area Under the Curve (AUC) approach to mobilized
CD34+CD38− cells within the first year of G-CSF treatment in
19 available patients, who all received ongoing 5-day treatment.
Longer surviving patients displayed a significantly superior
mobilization of CD34+CD38− cells under G-CSF application at
1 year of treatment. At 4 months this difference was borderline
significant (trend) (Figure 4).
Short and Long-Term Survivors Differed in
Their Baseline Cytokine Levels
Survival in months from diagnosis was negatively correlated
with baseline serum levels of the cytokine TNF-beta. MCP-1
and INF-gamma were, as a trend, negatively correlated with
survival as well. IL-16 baseline levels displayed a positive
correlation with survival. MDC, IL-8, IL-17A, and PIGF were,
as a trend, positively correlated with survival (Table 2, Figure 5).
We then dichotomized G-CSF treated patients according to
their survival of either more or less than 30 months from
diagnosis, and analyzed cytokines at baseline. Patients who
survived longer than 30 months from diagnosis had significantly
higher baseline levels of MDC and Tie-2. For IL-16, IL-17A,
and PIGF we found similar trends. On the other hand, there
were significantly higher baseline levels of TNF-beta and IL-7
in patients who survived less than 30 months from diagnosis.
TNF-alpha and MCP-1 displayed similar trends. However,
when correcting the cytokine comparisons in long and short
survival for multiple testing, none of these findings remained
significant [as assessed by the FDR-adjusted p-values (q-values)
in Table 2].
G-CSF Treatment Modulated Serum
Cytokine Levels of ALS Patients Over Time
The direct effects of G-CSF on cytokine levels were evaluated
by comparing cytokine levels 2 days prior to and 1 day after
ongoing 5-day G-CSF application in a subgroup of patients
allowing this analysis. These immediate effects were determined
at three different time points (baseline, 3 and 6 months after
treatment initiation). Due to individual application modes,
5-day G-CSF applications with corresponding blood samples
were available for 18 patients at baseline, for 17 patients at 3
months, and for 14 patients at 6 months of ongoing G-CSF
treatment.
We found G-CSF to have an immediate effect on the level of
various cytokines (Table 3, Figure S3). The serum level of IL-10
increased after 5 days of G-CSF treatment at baseline, 3 months
and 6 months compared to its respective level before G-CSF
application, however, at 3months only as a trend. The levels of IL-
16, Tie-2, TNF-alpha, MIP1-beta, IL-15, IP-10, VCAM, ICAM-1,
and of Flt-1 were significantly increased after G-CSF treatment at
all above-mentioned time points. The levels of TARC, IL-7, INF-
gamma, and MCP-1 were decreased at all above-mentioned time
points. There was an increase in SAA, IL-12/IL-23p40, CRP, and
VEGF-A levels after G-CSF at baseline and 6 months, the latter at
6 months only as a trend. The levels of VEGF-C and PIGF were
increased after G-CSF at 6 months, that of PIGF also at 3 months
as a trend. There was a decrease of Eotaxin-1, Eotaxin-3 and
VEGF-D after G-CSF application at baseline and 3months. TNF-
beta was decreased at baseline, at 6 months by a trend. MCP-4
was decreased at 6 months, at baseline by a trend. The level of
bFGF was decreased after G-CSF application at 3 months and 6
months.
DISCUSSION
Our Main Findings
Long term and individually adapted off-label treatment with
G-CSF in 36 ALS patients was well tolerated and safe.
The number of G-CSF-mobilized hematopoietic stem cells, as
measured by AUC, was associated with longer survival. Initial
levels of serum cytokines, such as MDC, TNF-beta, IL-7, IL-16,
and Tie-2 were significantly associated with survival, indicating
the potential of prognostic application of these immune markers
in G-CSF treated ALS patients. Continued application of G-
CSF led to persistent alterations in various serum cytokines
and ongoing measurements revealed the multifaceted effects of
G-CSF.
ALS as a Neuroinflammatory Disease
ALS has been recognized as a multifactorial disease.
Neurodegenerative processes trigger neuroinflammation
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FIGURE 3 | (A,B) Mobilization of hematopoietic stem cells (HSPC) in G-CSF treated ALS patients. Plotted are CD34+ (Figure 2A) and CD34+CD38− HSPC
(Figure 2B) in blood 2 days before (d0) and 1 day after (d7) daily application of G-CSF over 5 days in 16 (for CD34+)/15 (for CD34+CD38−) patients at baseline, in 17
patients after 3 months, and in 14 (for CD34+)/13 (for CD34+CD38−) patients after 6 months of treatment. Data are presented as scatter dot plot with mean + SEM.
Paired Wilcoxon t-test, significance was taken at p < 0.05 (two-tailed). T-tests were corrected for multiple testing by FDR-adjusted p-values (q-values), discovery is
indicated by q < 0.1. In CD34+ and CD34+CD38− HSPC at all time points: q-value = 0.0002.
FIGURE 4 | Mobilization of CD34+CD38− HSPC is associated with survival in ALS patients on a 5-day treatment scheme with G-CSF. Area under the curve (AUC)
approach on blood HSPC over 4 months (A) and 1 year (B) in patients treated with 5-day application of G-CSF (n = 20). Patients were assigned survival groups
dependent on survival being longer (high survival n = 8) or shorter (low survival) than 30 months from diagnosis.
and vice versa. Neuroinflammation with microglial activation,
infiltration of peripheral immune cells into the CNS, and
alterations in cytokine levels are pathological features in ALS.
Cytokines aremediators of the immune communication thatmay
cross the blood-brain barrier (BBB) and provide a mechanism
by which the peripheral immune system may directly influence
the CNS (30). In a recent study, we demonstrated a pro-
inflammatory immune response with elevated inflammatory
cytokines both in serum during disease and post-mortem in
the CNS of ALS patients (31). However, immune response in
ALS cannot be clearly dichotomized to a purely pro- or anti-
inflammatory state, as cytokines are often pleiotropic, and their
function may change over time and depend on concentration
and specific disease context. Possibly, cytokine response in early
ALS may be an attempt to restore homeostatic balance, whereas
chronic exposure to pro-inflammatory cytokines might lead
to cell destruction and loss of neuronal function. The latter
supports a self-sustaining inflammatory process and possibly
accelerates disease progression (7). Neuroinflammation and
systemic inflammatory stimuli with their influence upon the
CNS offer targets for therapeutic intervention in ALS (32).
Analysis of peripheral blood is a feasible alternative for ongoing
measurements of immune mediated and pathophysiological
relevant parameters (33).
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TABLE 2 | Cytokine levels at baseline in relation to survival.
Cytokine Level in long survival Correlation Comparison (t-test)
r-value R2-value p-value Median long survival Median short survival p-value q-value
ANTI-INFLAMMATORY
MDC 0.3269 0.1069 0.0726 939 227 0.0494 0.3088
PRO-INFLAMMATORY
TNF-ß −0.4981 0.2481 0.0043 0.535 0.830 0.0038 0.1254
IL-7 – – – 17 27 0.0171 0.2640
TNF-α – – – 2.5 3.0 0.0638 0.3088
MCP-1 −0.3414 0.1166 0.0601 278 957 0.0544 0.3088
INF-γ −0.3264 0.1065 0.0731 – – – –
IL-16 0.4449 0.1979 0.0122 262 133 0.0655 0.3088
IL-8 0.3492 0.1219 0.0542 – – – –
IL-17A 0.3749 0.1406 0.0710 2.58 0.68 0.0912 0.3421
ANGIOGENESIS
Tie-2 – – – 5762 4492 0.0240 0.2640
PIGF 0.3277 0.1074 0.0719 33.8 31.7 0.0933 0.3421
Cytokine levels in pg/ml before first G-CSF application in ALS patients. Arrows indicate cytokine levels in patients with long compared to short survival. Then cytokine levels at baseline
were correlated with survival. Next, Mann-Whitney test was calculated to assess differences in baseline cytokine levels in patients with survival longer or shorter than 30 months from
diagnosis. Number of patients at baseline: 31 (16 long survival). Significance is indicated by bold marking when p < 0.05 (two-tailed p-value), trend when p < 0.1. T-tests were corrected
for multiple testing by FDR-adjusted p-values (q-values), discovery is indicated by q < 0.1.
G-CSF in ALS
ALS is a multifactorial disease. Targeting common pathologic
features such as neuro-inflammation and -degeneration may
thus be beneficial for all ALS patients. Although G-CSF
is an established, well-tolerated and safe growth factor for
mobilization of hematopoietic stem and precursor cells (34),
there is accumulating evidence that it is also a potent
modulator of multiple CNS functions relevant to ALS (13). G-
CSF modulates the immune response (35), it promotes anti-
inflammatory and decreases pro-inflammatory mediators (36).
Small clinical trials with G-CSF in ALS patients have delivered
inconclusive results. Treatment with G-CSF was associated with
a decrease in pro-inflammatory cytokine levels in serum and
cerebrospinal fluid (CSF) of ALS patients (26), andminor benefits
were detected by neuroimaging (27). But promising evidence
for efficacy of G-CSF in ALS animal models has not yet been
translated to ALS patients. It seems likely that a successful clinical
translation requires higher dose, more frequent application and
longer exposure to G-CSF as well as extended observation times
(37). The latter is of crucial importance when aiming at structural
and functional improvements or support of neurogenesis.
G-CSF Treatment in ALS Is Safe and Well
Tolerated
Application of G-CSF in oncological indications is usually limited
to treatment cycles, and the only clinical experience with life-
long G-CSF therapy has accumulated with patients suffering
from severe congenital neutropenia and cyclic neutropenia (38,
39). To our knowledge, we first reported on long-term G-CSF
treatment in a CNS indication (25). We found G-CSF application
to be generally well tolerated in ALS patients, with mild to
moderate bone pain and leukocytosis after G-CSF applications as
frequentminor adverse events. As this was off-label, experimental
treatment of individual ALS patients, we had no control group
for assessment of survival. If we only observe deceased patients
and leave those still alive out, then the mean survival of these
26 patients at 25.5 months from diagnosis indicates no harm by
G-CSF in ALS.
Stem Cell Mobilization Is Efficient and
Associated With Longer Survival in G-CSF
Treated ALS Patients
G-CSF is a well-known mobilizer of hematopoietic stem cells (8,
9). In all patients treated with G-CSF for five consecutive days, G-
CSF increased mobilization of hematopoietic stem cells (CD34+
and CD34+ CD38−) into the peripheral blood. Interestingly,
we found an association between stem cell mobilization and
survival. Patients who survived longer than 30 months from
diagnosis mobilized more CD34+CD38− hematopoietic stem
cells than patients with shorter survival, as measured by
Area Under the Curve after G-CSF treatment up to 1 year
(Figure 4). Higher levels of circulating hematopoietic stem cells
are associated with better clinical outcome and less structural
damage after intracerebral hemorrhage in humans (40). The
mechanism of how hematopoietic stem cells may contribute
to neurodegenerative disease is yet unclear. Migration and
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FIGURE 5 | (A–D) Baseline cytokine levels are associated with survival in G-CSF treated ALS patients. Plotted are initial cytokine levels of TNF beta (A), IL-16 (B), IL-8
(C), MCP-1 (D), IL-17A (E), MDC (F), ING gamma (G), and PIGF (H) in pg/ml before first G-CSF application in 31 patients. Survival was assessed in months from
diagnosis and censored upon data admission in living patients (n = 7). Displayed is Pearson r, the coefficient of determination (R2), p-value (two-tailed) significant at p
< 0.05, trend at p < 0.1.
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TABLE 3 | Cytokine levels before and after G-CSF treatment at different time points.
Cytokine Direction Treatment start 3 months 6 months
Fold change
d0-d7
p-value q-value Fold change
d0-d7
p-value q-value Fold change
d0-d7
p-value q-value
ANTI-INFLAMMATORY
IL-10 1.95 0.0016 0.0018 1.24 0.0856 0.0371 2.02 0.0004 0.0007
PRO-INFLAMMATORY
TNF-ß 0.83 0.0208 0.0112 – – – 0.85 0.0591 0.0268
INF-γ 0.81 0.0214 0.0113 0.78 0.0182 0.0104 0.62 0.0009 0.0014
IL-7 0.66 0.0003 0.0006 0.80 0.0011 0.0014 0.80 0.0107 0.0075
MCP-1 0.83 0.0120 0.0080 0.77 0.0007 0.0012 0.79 0.0107 0.0075
MCP-4 0.94 0.0599 0.0268 0.92 0.0150 0.0089 – – –
TARC 0.87 0.0304 0.0148 0.86 0.0032 0.0030 0.80 0.0166 0.0097
Eotaxin-1 0.88 0.0139 0.0085 0.93 0.0079 0.0059 – – –
Eotaxin-3 0.83 0.0034 0.0030 0.78 0.0034 0.0030 – – –
CRP 4.45 0.0010 0.0014 – – – 3.99 0.0085 0.0062
SAA 2.96 0.0008 0.0013 – – – 2.03 0.0353 0.0168
TNF-α 1.77 <0.0001 0.0003 1.50 0.0046 0.0038 1.79 0.0004 0.0007
IP-10 1.50 0.0002 0.0004 1.34 0.0067 0.0052 1.40 0.0134 0.0085
IL-15 1.14 0.0022 0.0022 1.24 0.0208 0.0112 1.24 0.0016 0.0018
IL-12/IL-23p40 1.24 0.0047 0.0038 – – – 1.19 0.0052 0.0041
IL-16 3.14 <0.0001 0.0003 3.66 0.0011 0.0014 3.78 0.0002 0.0004
MIP1-ß 3.38 <0.0001 0.0003 4.63 0.0013 0.0015 2.91 0.0001 0.0003
ANGIOGENESIS
VEGF-A 1.39 0.0010 0.0014 – – – 1.32 0.0580 0.0268
Tie-2 1.27 <0.0001 0.0003 1.18 0.0032 0.0030 1.19 0.0134 0.0085
Flt-1 1.45 <0.0001 0.0003 1.32 0.0026 0.0026 1.33 0.0001 0.0003
PIGF – – – – – – 1.14 0.0203 0.0112
VEGF-C – – – 0.0984 0.0420 0.86 0.0017 0.0017
VEGF-D 0.88 0.0139 0.0085 0.94 0.0110 0.0075 – – –
bFGF – – – 0.72 0.0232 0.0121 0.81 0.0040 0.0035
VASCULAR INJURY
VCAM 1.40 <0.0001 0.0003 1.28 0.0267 0.0134 1.41 0.0001 0.0003
ICAM-1 1.30 <0.0001 0.0003 1.23 0.0305 0.0148 1.31 0.0001 0.0003
Paired Wilcoxon t-test. Arrows indicate direction, and fold change gives effect size of cytokine modulation when comparing respective levels 2 days before (d0) and 1 day after (d7)
daily application of G-CSF over 5 days. Number of evaluable patients at baseline: 18, at 3 months: 17, and at 6 months: 14. Significance is indicated by bold marking when p < 0.05
(two-tailed p-value), trend when p < 0.1. T-tests were corrected for multiple testing by FDR-adjusted p-values (q-values), discovery is indicated by q < 0.1. Non-significant and non-trend
findings are marked by -.
subsequent trans-differentiation of bone marrow derived cells
within the CNS is controversially discussed (18). However,
G-CSF increases the number of hematopoietic stem cells
translocated to the damaged CNS (16, 17). There, hematopoietic
stem cells modulate the immune system, they may interact with
local cells, and produce neurotrophic factors, which promote
growth of neural progenitors and survival (17, 18). A recent study
in mice exposed to cranial irradiation demonstrated that G-CSF
augments neurogenesis; bone marrow derived G-CSF-responsive
cells migrate to the CNS, where they express macrophage and
microglia phenotypes. The authors found that G-CSF treatment
led to an improved functional outcome, thus arguing for the
Frontiers in Neurology | www.frontiersin.org 10 November 2018 | Volume 9 | Article 971
Johannesen et al. G-CSF in ALS
neuroprotective mechanisms of G-CSF on brain repair (15).
Human studies have demonstrated G-CSF to directly affect
monocytes and to modulate monocyte cytokine secretion toward
an anti-inflammatory polarization (41). A recent study applying
G-CSF in healthy humans described expansion of a mature
variant monocyte subtype displaying strong immunosuppressive
properties (42). Next to neural cells, also neural stem cells have G-
CSF receptors and G-CSF treatment induces a neural phenotype
of these cells (12). Effects of G-CSF on hematopoietic stem cells
may therefore serve as a proxy for biological cellular activity of
G-CSF on neural cells.
Cytokine Levels Are Associated to Survival
and Affected by G-CSF
Neuroinflammation contributes to the pathogenesis of ALS (3).
Apart from CNS inflammation, peripheral cytokines and other
inflammatory markers are affected in ALS, and cytokine levels
may serve as biomarkers (43). We found that different cytokines
at baseline were correlated with survival (Table 2, Figure 5).
When dichotomizing patients depending on individual survival
being longer or shorter than 30 months from diagnosis, we
detected different peripheral cytokine levels at baseline (Table 2).
In general, five-day treatment courses with G-CSF exerted
immediate effects on cytokine levels and were able to partly
counteract the harmful immune response in ALS (Table 3,
Figure S3).
The initial levels of 11 cytokines were associated with survival,
of which 8 were altered by G-CSF application. However, the
correlation models, as indicated by the rather low R2-values,
could only explain smaller parts of the variance. Even though
the cytokine comparisons in long and short survival did not
withstand correction for multiple testing, we decided to explore
the findings because they might help to generate hypotheses
for further studies and show biologically important findings
in spite of the small number of patients tested. Moreover, G-
CSF led to change in many inflammatory cytokines, as well as
cytokines involved in angiogenesis and vascular injury, of which
all significant changes remained so after testing for multiple
comparison (Tables 2, 3).
Initial TNF-beta (LTA, lymphotoxin-alpha) levels negatively
correlated with survival and were found at higher levels in
shorter surviving ALS patients upon treatment initiation. G-CSF
application led to reduction in TNF-beta, a pro-inflammatory
cytokine and common cell death effector found to be increased
in ALS sera (31). TNF-alpha was borderline increased in patients
with shorter survival (trend) and G-CSF led to an increase
in its serum levels. TNF-alpha is elevated in ALS (31, 43–46)
and correlates with disease duration (47). But its role in ALS
in unclear and the two TNF-alpha receptors, either associated
with inflammation or neuroprotection, have opposing effects
concerning survival in ALS (48). Dependent on subtype and
context, activation can lead to neuroprotection and neurogenesis
(49), reduced oxidative stress (50) and glutamate excitotoxicity
(51). An increased occurrence of ALS after long-term use of
TNF-alpha inhibitors in rheumatic arthritis, is suggested to
be a consequence of deficient TNF-alpha mediated neuronal
protection (52). Higher initial levels of IL-7 were associated with
shorter survival, and reduced after ongoing treatment with G-
CSF. IL-7 is considered a pro-inflammatory cytokine, and is
increased in CSF (53) and serum (31) of ALS patients. MCP-1
(CCL2) was borderline correlated (trend) with shorter survival
of ALS patients. We confirmed a reduction of MCP-1 levels in
ALS after treatment with G-CSF (26). MCP-1 is a prominent pro-
inflammatory cytokine that can enhance microglial recruitment
to the CNS after injury, which may exacerbate ALS progression
(54). MCP-1 correlates with faster disease progression (55) and
ALS patients have elevated MCP-1 serum levels (31, 55, 56) and
increased protein expression within spinal cord (31). INF-gamma
was borderline negatively correlated with survival in our patients
(trend). As known from healthy donors (57), INF-gamma levels
were decreased by G-CSF. As a hallmark of proinflammatory
cells, INF-gamma is proposed to contribute to motor neuron
death in ALS (58). ALS patients have higher INF-gamma serum
levels (47, 55, 59), that correlate with disease progression (47, 59)
and shorter survival (55).
On the other hand, the pro-inflammatory marker IL-16 was
positively correlated with survival and increased after G-CSF
application. IL-16 also holds an immunomodulatory role by
expansion of regulatory T cells (Treg) (60), that at lower levels
in ALS, are associated with rapid disease progression and shorter
survival (61). Thus, G-CSF related increase in IL-16 might be
beneficial for ALS patients. Another pro-inflammatory cytokine,
IL-17A, was borderline correlated with longer survival (trend)
but not altered by G-CSF treatment. IL-17A has been reported
elevated in serum (55, 62, 63) and CSF (64) of ALS patients.
After G-CSF treatment, Chió et al. found a reduction of IL-
17A in the CSF, but not in serum of ALS patients (26). IL-8
was borderline correlated with longer survival (trend), and not
altered by G-CSF treatment. IL-8 is produced by several cells
in response to inflammation, and higher plasma (44) and CSF
levels (65) are known in ALS. MDC (CCL22) was associated with
longer survival, however, not modulated by G-CSF treatment.
MDC is an anti-inflammatory cytokine, and consistent with
a proposed protective effect, ALS patients have lower MDC
protein expression in the spinal cord (31). Further, angiogenic
factors, such as Tie-2 and PIGF were associated with survival.
Tie-2 was elevated in longer surviving patients and G-CSF led
to an increase in it’s serum levels. Angiogenesis is mediated
by the angiopoietin-1/Tie-2 system (66), and stimulation of
angiogenesis by another pro-angiogenic factor, VEGF, is found
to increase neurogenesis (19). G-CSF treatment led to an
increase in PIGF, and PIGF was as a trend both correlated with
survival and elevated in longer surviving patients. PIGF supports
angiogenesis (67), and may be a marker for the angiogenic
niche.
The following 18 cytokines were significantly altered by G-
CSF, however, not associated with survival. As known from
healthy donors (68), IL-10 was markedly increased after G-
CSF treatment. This anti-inflammatory cytokine is elevated in
ALS-patients with mild symptoms or slow progression (53).
G-CSF application led to reduced systemic levels of the pro-
inflammatory cytokines MCP-4 (CCL13), TARC, Eotaxin-1
(CCL11), and Eotaxin-3 (CCL26). MCP-4 (31, 65), TARC (31)
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and Eotaxin-1 (65) are elevated in ALS serum. The latter is
further associated with Alzheimer’s dementia (69), aging and
inhibition of neurogenesis in mice (70). We also noticed increase
in levels of the pro-inflammatory cytokines CRP, SAA, IP-10
(CXCL10), IL-15, IL-12/IL-23p40, and MIP1-beta after G-CSF
application. The acute-phase proteins CRP and SAA have been
described as elevated in ALS patients (31, 71). IP-10 is negatively
correlated with disease progression rate (72) and increase after
G-CSF treatment has been described (26). IL-15 (31, 55, 73) and
MIP1-beta (31) are elevated in serum of ALS patients. MIP1-beta
shares receptor (CCR5) with MIP-alpha, which is elevated and
considered neuroprotective in ALS (74). MIP-1 beta is negatively
correlated with disease severity and progression rate, and thus
might exert neuroprotective effects in ALS (72). IL-12/IL-23p40
describes the p40 subunit shared by the cytokines IL-12 and IL-
23, and is considered a pro-inflammatory marker. However, we
noted no increase in cytokines induced by IL-12/IL-23p40, such
as INF-gamma and IL-17A, after G-CSF treatment. Aside from
neuroinflammation, impaired neurotrophic support is a hallmark
of ALS. Levels of VEGF-A and Flt-1 were increased, whereas
VEGF-C, VEGF-D, and bFGF levels were decreased after G-
CSF application. VEGF-A and bFGF, two common neurotrophic
and possibly protective factors in ALS (55), are both increased
in ALS CSF (64). Further, VEGF-A supports neurogenesis and
neural development and is an attractant for HSPC that has
been associated with longer survival in ALS (55). We found an
increase in ICAM-1 and VCAM-1 after G-CSF treatment. At
the vascular endothelium these cellular adhesion molecules are
involved in leukocyte transport (75), but their role in ALS is
unclear.
In ALS, a short time delay for diagnosis is associated
with inferior prognosis as these patients are likely to have
a more aggressive disease (76). Accordingly, we observed a
briefer latency between diagnosis and treatment initiation in
patients with shorter survival, which might reflect a more
rapid progression of disease in these patients. Hence, longer
surviving patients presumably initiated treatment at a later
pathophysiological stage of their disease. This might offer an
explanation for the fact that levels of some pro-inflammatory
cytokines such as IL-16, IL-17A, and IL-8 were associated with
longer survival. However, the role of inflammatory markers
in ALS is unclear and our findings may also indicate that
inflammation does not only negatively impact the disease (71).
The remaining relation between cytokines and survival seen
in our cohort highlights the importance of these markers
in predicting individual survival. Thus, different cytokines
may be used as biomarkers for initial patient stratification,
predicting later clinical course, monitoring treatment response
and progression of disease.
Possible direct effects of G-CSF upon the CNS were not
assessed, as we did not obtain post-mortem analysis of deceased
patients. Neuroimaging studies conducted on our G-CSF treated
patient cohort (77) did not directly address possible G-CSF
related structural effects—we also had no patient control group
without G-CSF treatment. One indirect mode of action by
which G-CSF exerts neuroprotective effects may be through
polarization of the immune system toward an anti-inflammatory
state (13). We observed an increase in anti-inflammatory
cytokines and neurotrophic factors as well as a decrease in pro-
inflammatory cytokines. However, we also captured an increase
in some pro-inflammatory cytokines, which might be due to the
pleiotropic effects of G-CSF and possibly reflect an unspecific
cytokine reaction after application. Overall, the effects of G-CSF
on peripheral cytokine levels and ALS appear to be versatile and
should be assessed in a prospective clinical study.
Strengths and Limitations
This retrospective analysis has several limitations. Firstly, we
have not conducted a controlled clinical trial and thus, there
was no placebo-arm. Rather, the aim of the intervention was
to offer individual ALS patients a potentially beneficial off-label
treatment with G-CSF. Evaluation of respiratory function was
driven by clinical indication and not systematically assessed.
Hence, we did not regularly screen for respiratory deficits
upon treatment initiation. The same applied to assessment of
cognitive function. In addition, we did not systematically analyze
for ALS-specific gene mutations. Such factors have predictive
value concerning prognosis (78), the lack of initial screening of
respiratory and cognitive function as well as genetic background
might impede interpretation of the data. Given the objective of
evaluating safety of G-CSF and the absence of a control group, in
this paper we assessed survival from time of diagnosis, and not
from treatment initiation. The latency between symptom onset
and diagnosis was not assessed in this report. This is a limitation,
as quantification of diagnostic delay - being associated with
longer survival (78), could have offered prognostic implications.
During the experimental treatment, patients were routinely seen
on an outpatient basis to monitor safety and blood samples
were regularly obtained. This enabled a dynamic observation
of alterations in neuroinflammation due to ALS disease and
treatment with G-CSF over time. However, with only 36 G-CSF
treated patients caution should be applied in trying to generalize
our findings. Moreover, application and dosing schemes for
G-CSF treatment were decided upon on an individual patient
level and thus complicated the establishment of dose-effect
relationships. When we analyze cytokine levels upon treatment
initiation in our patient cohort retrospectively, we have to take
into account that these patients differ concerning covariant
factors such as age, gender, bulbar vs. spinal-onset, and functional
status (ALSFRS-R). Given the small number of patients treated
with G-CSF, a statistical evaluation of the predictive value of
these subpopulations was not reasonable. There was also great
heterogeneity in the latency between time of diagnosis and
treatment initiation. Cytokine levels alter during progression of
disease. Altogether, these aspects lead to a reduced statistical
power, which may also provide an explanation for the variation
and modest correlation seen between initial cytokine levels and
survival. Moreover, we found that cytokine comparisons in long
and short surviving patients did not withstand correction for
multiple testing. These signals may be of biological relevance, as
they were detected in spite of a small number of patients and
great disease heterogeneity, and thus may assist in hypothesis
generation for future studies.
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CONCLUSION
Altogether, we found that long term G-CSF treatment is
feasible and safe for ALS patients. G-CSF efficiently mobilized
hematopoietic stem cell into peripheral blood, and the amount
of mobilized stem cells was associated with longer survival. Thus,
stem cell mobilization could be a potential biomarker to monitor
treatment response to G-CSF. Peripheral cytokines are relevant in
the course of disease in ALS. We identified TNF-beta, MDC, IL-
16, IL-7, and Tie-2 as cytokines whose baseline levels may predict
G-CSF treatment response and survival. Additionally, long
term G-CSF treatment led to sustained alterations of multiple
cytokines in peripheral blood. Thus, cytokines represent potential
biomarkers for survival prediction and for early monitoring of G-
CSF treatment in ALS, all of which need further validation in a
prospective controlled randomized trial.
AUTHOR CONTRIBUTIONS
SJ care for ALS patients, conception of intervention, analysis,
interpretation, wrote the manuscript. UB clinical responsibility
for intervention. UB, WS-M, and VS care for ALS patients,
conception of intervention and analysis, revision of the
manuscript. T-HB conception of intervention and analysis,
revision of the manuscript. BB contribution to analysis, revision
of the manuscript. A-LM care for ALS patients, revision of the
manuscript. TK organization of care and disposition of patient
material. SP and EW performed cytokine experiments, revision
of the manuscript. SI and JG performed and analyzed HSPC
experiments, revision of the manuscript. AS and WH revision of
the manuscript.
FUNDING
Biomarker analysis was funded by BMBF grant GO-Bio
CampoNeuro, and BayMWiT grant CrossTalk.
ACKNOWLEDGMENTS
The authors are grateful to all participating patients and their
families. The authors are thankful to Andrei Khomenko (MD),
Dobri Baldaranov (MD), Jenni Rösl (MD) and Ohnmar Hsam
(MD) for sustained treatment of patients, and to Ines Kobor (MS)
for assistance in maintenance of the database.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fneur.
2018.00971/full#supplementary-material
REFERENCES
1. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and
management of amyotrophic lateral sclerosis. Nature Rev Neurol. (2011)
7:639–49. doi: 10.1038/nrneurol.2011.153
2. Alonso A, Logroscino G, Jick SS, Hernán MA. Incidence and lifetime risk of
motor neuron disease in the United Kingdom: a population-based study. Eur
J Neurol. (2009) 16:745–51. doi: 10.1111/j.1468-1331.2009.02586.x
3. Hardiman O, Al-Chalabi A, Chiò A, Corr EM, Logroscino G, Robberecht W,
et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. (2017) 3:17071–19.
doi: 10.1038/nrdp.2017.71
4. Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and
epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population,
1997-2011. Neurology (2013) 3:313–20. doi: 10.1212/CPJ.0b013e3182a1b8ab
5. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-
ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic
Lateral Sclerosis/Riluzole Study Group II. Lancet (1996) 347:1425–31.
doi: 10.1016/S0140-6736(96)91680-3
6. Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al. Safety and efficacy
of edaravone in well defined patients with amyotrophic lateral sclerosis: a
randomised, double-blind, placebo-controlled trial. Lancet Neurol. (2017)
16:505–12. doi: 10.1016/S1474-4422(17)30115-1
7. Becher B, Spath S, Goverman J. Cytokine networks in neuroinflammation.
Nature Publishing Group (2017) 17:49–59. doi: 10.1038/nri.2016.123
8. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its
receptor. Blood. (1991) 78:2791–808.
9. Welte K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R, et
al. Purification and biochemical characterization of human pluripotent
hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA. (1985)
82:1526–30. doi: 10.1073/pnas.82.5.1526
10. Hartung T. Anti-inflammatory effects of granulocyte colony-
stimulating factor. Curr Opin Hematol. (1998) 5:221–5.
doi: 10.1097/00062752-199805000-00013
11. Root RK, Dale DC. Granulocyte colony-stimulating factor and granulocyte-
macrophage colony-stimulating factor: comparisons and potential for use in
the treatment of infections in nonneutropenic patients. J Infect Dis. (1999) 179
(Suppl 2):S342–52. doi: 10.1086/513857
12. Schneider A, Krüger C, Steigleder T, Weber D, Pitzer C, Laage R, et
al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts
programmed cell death and drives neurogenesis. J Clin Invest. (2005)
115:2083–98. doi: 10.1172/JCI23559
13. Wallner S, Peters S, Pitzer C, Resch H, Bogdahn U, Schneider
A. The Granulocyte-colony stimulating factor has a dual role in
neuronal and vascular plasticity. Front Cell Dev Biol. (2015) 3:1–13.
doi: 10.3389/fcell.2015.00048
14. Henriques A, Pitzer C, Dupuis L, Schneider A. G-CSF protects motoneurons
against axotomy-induced apoptotic death in neonatal mice. BMC Neurosci.
(2010) 11:25. doi: 10.1186/1471-2202-11-25
15. Dietrich J, Baryawno N, Nayyar N, Valtis YK, Yang B, Ly I, et al. Bone marrow
drives central nervous system regeneration after radiation injury. J Clin Invest.
(2018) 128:281–93. doi: 10.1172/JCI90647
16. Koda M, Nishio Y, Kamada T, Someya Y, Okawa A, Mori C, et al. Granulocyte
colony-stimulating factor (G-CSF) mobilizes bone marrow-derived cells into
injured spinal cord and promotes functional recovery after compression-
induced spinal cord injury in mice. Brain Research. (2007) 1149:223–31.
doi: 10.1016/j.brainres.2007.02.058
17. Xiao B-G, Lu C-Z, Link H. Cell biology and clinical promise of G-CSF:
immunomodulation and neuroprotection. J Cell Mol Med. (2007) 11:1272–90.
doi: 10.1111/j.1582-4934.2007.00101.x
18. Schneider A, KuhnH-G, SchäbitzW-R. A role for G-CSF (granulocyte-colony
stimulating factor) in the central nervous system. Cell Cycle. (2005) 4:1753–7.
doi: 10.4161/cc.4.12.2213
19. Schanzer A, Wachs FP, Wilhelm D, Acker T, Cooper-Kuhn C, Beck H, et al.
Direct stimulation of adult neural stem cells in vitro and neurogenesis in
vivo by vascular endothelial growth factor. Brain Pathol. (2004) 14:237–48.
doi: 10.1111/j.1750-3639.2004.tb00060.x
20. Henriques A, Pitzer C, Dittgen T, KlugmannM, Dupuis L, Schneider A. CNS-
targeted viral delivery of G-CSF in an animalmodel for ALS: improved efficacy
and preservation of the neuromuscular unit. Mol Ther. (2011) 19:284–92.
doi: 10.1038/mt.2010.271
Frontiers in Neurology | www.frontiersin.org 13 November 2018 | Volume 9 | Article 971
Johannesen et al. G-CSF in ALS
21. Schneider A, Pitzer C, Henriques A, Kruger C, Plaas C, Kirsch F,
et al. Granulocyte-colony stimulating factor improves outcome in a
mouse model of amyotrophic lateral sclerosis. Brain (2008) 131:3335–47.
doi: 10.1093/brain/awn243
22. Pollari E, Savchenko E, Jaronen M, Kanninen K, Malm T, Wojciechowski
S, et al. Granulocyte colony stimulating factor attenuatesinflammation in a
mouse model of amyotrophiclateral sclerosis. J Neuroinflam. (2011) 8:74.
doi: 10.1186/1742-2094-8-74
23. Zhang Y, Wang L, Fu Y, Song H, Zhao H, Deng M, et al. Preliminary
investigation of effect of granulocyte colony stimulating factor on
amyotrophic lateral sclerosis. Amyotroph Lateral Scler. (2009) 10:430–1.
doi: 10.3109/17482960802588059
24. Nefussy B, Artamonov I, Deutsch V, Naparstek E, Nagler A, Drory VE.
Recombinant human granulocyte-colony stimulating factor administration
for treating amyotrophic lateral sclerosis: a pilot study. Amyotroph Lateral
Scler. (2010) 11:187–93. doi: 10.3109/17482960902933809
25. Grassinger J, Khomenko A, Hart C, Baldaranov D, Johannesen S, Mueller
G, et al. Safety and feasibility of long term administration of recombinant
human granulocyte-colony stimulating factor in patients with amyotrophic
lateral sclerosis. Cytokine (2014) 67:21–8. doi: 10.1016/j.cyto.2014.02.003
26. Chiò A, Mora G, Bella VL, Caponnetto C, Mancardi G, Sabatelli M, et al.
Repeated courses of granulocyte colony-stimulating factor in amyotrophic
lateral sclerosis: clinical and biological results from a prospective multicenter
study.Muscle Nerve (2011) 43:189–95. doi: 10.1002/mus.21851
27. Duning T, Schiffbauer H,Warnecke T, Mohammadi S, Floel A, Kolpatzik K, et
al. G-CSF Prevents the progression of structural disintegration of white matter
tracts in amyotrophic lateral sclerosis: a pilot trial. PLoS ONE (2011) 6:e17770.
doi: 10.1371/journal.pone.0017770
28. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of
Neurology Research Group on Motor Neuron Diseases. El Escorial
revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Other Motor Neuron Disord. (2000) 1:293–9.
doi: 10.1080/146608200300079536
29. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond
B, et al. The ALSFRS-R: a revised ALS functional rating scale that
incorporates assessments of respiratory function. J Neurol Sci. (1999) 169:13–
21. doi: 10.1016/S0022-510X(99)00210-5
30. Banks WA. The blood-brain barrier in neuroimmunology: tales of
separation and assimilation. Brain Behav Immun. (2015) 44:1–8.
doi: 10.1016/j.bbi.2014.08.007
31. Peters S, Zitzelsperger E, Kuespert S, Iberl S, Heydn R, Johannesen SW,
et al. The TGF-β System As a Potential Pathogenic Player in Disease
Modulation of Amyotrophic Lateral Sclerosis. Front Neurol. (2017) 8:181–20.
doi: 10.3389/fneur.2017.00669
32. Ransohoff RM. How neuroinflammation contributes to neurodegeneration.
Science (2016) 353:777–83. doi: 10.1126/science.aag2590
33. Vu LT, Bowser R. Fluid-based biomarkers for amyotrophic lateral sclerosis.
Neurotherapeutics (2017) 14:119–34. doi: 10.1007/s13311-016-0503-x
34. Roberts AW. G-CSF: A key regulator of neutrophil production, but that’s not
all! Growth Factors (2005) 23:33–41. doi: 10.1080/08977190500055836
35. Martins A, Han J, Kim SO. The multifaceted effects of granulocyte colony-
stimulating factor in immunomodulation and potential roles in intestinal
immune homeostasis. IUBMB Life (2010) 62:611–7. doi: 10.1002/iub.361
36. Hartung T, Döcke WD, Gantner F, Krieger G, Sauer A, Stevens P, et al. Effect
of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine
response in human volunteers. Blood. (1995) 85:2482–9. Available online at:
http://www.bloodjournal.org/content/85/9/2482
37. Henriques A, Pitzer C, Schneider A. Neurotrophic growth factors for the
treatment of amyotrophic lateral sclerosis: where do we stand? Front Neurosci.
(2010) 4:32. doi: 10.3389/fnins.2010.00032
38. Skokowa J, Dale DC, Touw IP, Zeidler C, Welte K. Severe congenital
neutropenias. Nat Rev Dis Primers (2017) 3:17032. doi: 10.1038/nrdp.2017.32
39. Dale DC, Bolyard A, Marrero T, Makaryan V, Bonilla M, Link DC, et al. Long-
term effects of G-CSF therapy in cyclic neutropenia. N Engl J Med. (2017)
377:2290–2. doi: 10.1056/NEJMc1709258
40. Sobrino T, Arias S, Pérez-Mato M, Agulla J, Brea D, Rodríguez-Yáñez M, et
al. Cd34+progenitor cells likely are involved in the good functional recovery
after intracerebral hemorrhage in humans. J Neurosci Res. (2011) 89:979–85.
doi: 10.1002/jnr.22627
41. Saito M, Kiyokawa N, Taguchi T, Suzuki K, Sekino T, Mimori K, et al.
Granulocyte colony-stimulating factor directly affects human monocytes
and modulates cytokine secretion. Exp Hematol. (2002) 30:1115–23.
doi: 10.1016/S0301-472X(02)00889-5
42. D’Aveni M, Rossignol J, Coman T, Sivakumaran S, Henderson S,
Manzo T, et al. G-CSF mobilizes CD34+ regulatory monocytes that
inhibit graft-versus-host disease. Sci Transl Med. (2015) 7:281ra42–2.
doi: 10.1126/scitranslmed.3010435
43. Hu Y, Cao C, Qin X-Y, Yu Y, Yuan J, Zhao Y, et al. Increased peripheral blood
inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis
study. Sci Rep. (2017) 7:9094. doi: 10.1038/s41598-017-09097-1
44. Lu C-H, Allen K, Oei F, Leoni E, Kuhle J, Tree T, et al. Systemic
inflammatory response and neuromuscular involvement in amyotrophic
lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. (2016) 3:e244–11.
doi: 10.1212/NXI.0000000000000244
45. Poloni M, Facchetti D, Mai R, Micheli A, Agnoletti L, Francolini G, et al.
Circulating levels of tumour necrosis factor-alpha and its soluble receptors are
increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci
Lett. (2000) 287:211–4. doi: 10.1016/S0304-3940(00)01177-0
46. Cereda C, Baiocchi C, Bongioanni P, Cova E, Guareschi S, Metelli MR, et al.
TNF and sTNFR1/2 plasma levels in ALS patients. J Neuroimmunol. (2008)
194:123–31. doi: 10.1016/j.jneuroim.2007.10.028
47. Babu GN, Kumar A, Chandra R, Puri SK, Kalita J, Misra UK. Elevated
inflammatory markers in a group of amyotrophic lateral sclerosis
patients from Northern India. Neurochem Res. (2008) 33:1145–9.
doi: 10.1007/s11064-007-9564-x
48. Tortarolo M, Coco Lo D, Veglianese P, Vallarola A, Giordana MT, Marcon
G, et al. Review articleamyotrophic lateral sclerosis, a multisystem pathology:
insights into the role of TNF. Mediators Inflamm. (2017) 2017:2985051.
doi: 10.1155/2017/2985051
49. Figiel I. Pro-inflammatory cytokine TNF-alpha as a neuroprotective agent in
the brain. Acta Neurobiol Exp. (2008) 68:526–34.
50. Fischer R, Maier O, Siegemund M, Wajant H, Scheurich P, Pfizenmaier
K. A TNF receptor 2 selective agonist rescues human neurons from
oxidative stress-induced cell death. PLoS ONE (2011) 6:e27621–11.
doi: 10.1371/journal.pone.0027621
51. Dolga AM, Granic I, Blank T, Knaus H-G, Spiess J, Luiten PGM, et al.
TNF-αmediates neuroprotection against glutamate-induced excitotoxicity via
NF-κB-dependent up-regulation of K Ca2.2 channels. J Neurochem. (2008)
107:1158–67. doi: 10.1111/j.1471-4159.2008.05701.x
52. Börjesson A, Grundmark B, Olaisson H,Waldenlind L. Is there a link between
amyotrophic lateral sclerosis and treatment with TNF-alpha inhibitors? Ups J
Med Sci. (2013) 118:199–200. doi: 10.3109/03009734.2013.785999
53. Furukawa T, Matsui N, Fujita K, Nodera H, Shimizu F, Miyamoto K, et
al. CSF cytokine profile distinguishes multifocal motor neuropathy from
progressive muscular atrophy. Neurol Neuroimmunol Neuroinflamm. (2015)
2:e138. doi: 10.1212/NXI.0000000000000138
54. Henkel JS, Engelhardt JI, Siklós L, Simpson EP, Kim SH, Pan T, et al.
Presence of dendritic cells, MCP-1, and activated microglia/macrophages in
amyotrophic lateral sclerosis spinal cord tissue.AnnNeurol. (2004) 55:221–35.
doi: 10.1002/ana.10805
55. Guo J, Yang X, Gao L, Zang D. Evaluating the levels of CSF and serum factors
in ALS. Brain Behav. (2017) 7:e00637–8. doi: 10.1002/brb3.637
56. Baron P, Bussini S, Cardin V, Corbo M, Conti G, Galimberti D, et al.
Production of monocyte chemoattractant protein-1 in amyotrophic lateral
sclerosis.Muscle Nerve. (2005) 32:541–4. doi: 10.1002/mus.20376
57. Rodríguez-Cortés O, Vela-Ojeda J, López-Santiago R, Montiel-Cervantes
L, Reyes-Maldonado E, Estrada-García I, et al. Granulocyte colony-
stimulating factor produces a decrease in IFNgamma and increase in IL-
4 when administrated to healthy donors. J Clin Apher. (2010) 25:181–7.
doi: 10.1002/jca.20234
58. Aebischer J, Cassina P, Otsmane B, Moumen A, Seilhean D, Meininger V,
et al. IFNγ triggers a LIGHT-dependent selective death of motoneurons
contributing to the non-cell-autonomous effects of mutant SOD1. Cell Death
Differ. (2011) 18:754–68. doi: 10.1038/cdd.2010.143
Frontiers in Neurology | www.frontiersin.org 14 November 2018 | Volume 9 | Article 971
Johannesen et al. G-CSF in ALS
59. Liu J, Gao L, Zang D. Elevated levels of IFN-γ in CSF and Serum of
patients with amyotrophic lateral sclerosis. PLoS ONE (2015) 10:e0136937.
doi: 10.1371/journal.pone.0136937
60. McFadden C, Morgan R, Rahangdale S, Green D, Yamasaki H, Center D, et
al. Preferential migration of T regulatory cells induced by IL-16. J Immunol.
(2007) 179:6439–45. doi: 10.4049/jimmunol.179.10.6439
61. Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel
JE, et al. Regulatory T-lymphocytes mediate amyotrophic lateral
sclerosis progression and survival. EMBO Mol Med. (2013) 5:64–79.
doi: 10.1002/emmm.201201544
62. FialaM, ChattopadhayM, La Cava A, Tse E, Liu G, Lourenco E, et al. IL-17A is
increased in the serum and in spinal cord CD8 and mast cells of ALS patients.
J Neuroinflam. (2010) 7:76. doi: 10.1186/1742-2094-7-76
63. Rentzos M, Rombos A, Nikolaou C, Zoga M, Zouvelou V, Dimitrakopoulos
A, et al. Interleukin-17 and interleukin-23 are elevated in serum and
cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation?
Acta Neurol Scand. (2010) 122:425–9. doi: 10.1111/j.1600-0404.2010.
01333.x
64. Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard
JL, Simmons Z, et al. A CSF biomarker panel for identification of
patients with amyotrophic lateral sclerosis. Neurology (2009) 72:14–9.
doi: 10.1212/01.wnl.0000333251.36681.a5
65. Kuhle J, Lindberg RLP, Regeniter A, Mehling M, Steck AJ, Kappos L, et al.
Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis.
Eur J Neurol. (2009) 16:771–4. doi: 10.1111/j.1468-1331.2009.02560.x
66. Zacharek A, Chen J, Li A, Cui X, Li Y, Roberts C, et al. Angiopoietin1/TIE2 and
VEGF/FLK1 induced by MSC treatment amplifies angiogenesis and vascular
stabilization after stroke. J Cereb Blood Flow Metab. (2007) 27:1684–91.
doi: 10.1038/sj.jcbfm.9600475
67. Takahashi H, Shibuya M. The vascular endothelial growth factor
(VEGF)/VEGF receptor system and its role under physiological
and pathological conditions. Clin Sci. (2005) 109:227–41.
doi: 10.1042/CS20040370
68. Fidyk W, Mitrus I, Ciomber A, Smagur A, Chwieduk A, Głowala-Kosinska
M, et al. Evaluation of proinflammatory and immunosuppressive cytokines in
blood and bone marrow of healthy hematopoietic stem cell donors. Cytokine.
(2017) 102:181–6. doi: 10.1016/j.cyto.2017.09.001
69. Bettcher BM, Fitch R, Wynn MJ, Lalli MA, Elofson J, Jastrzab L, et al. MCP-1
and eotaxin-1 selectively and negatively associate with memory in MCI and
Alzheimer’s disease dementia phenotypes. Alzheim Dement. (2016) 3:91–7.
doi: 10.1016/j.dadm.2016.05.004
70. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, et al. The ageing
systemic milieu negatively regulates neurogenesis and cognitive function.
Nature (2011) 477:90–4. doi: 10.1038/nature10357
71. Lunetta C, Lizio A, Maestri E, Sansone VA, Mora G, Miller RG, et
al. Serum C-Reactive protein as a prognostic biomarker in amyotrophic
lateral sclerosis. JAMA Neurol. (2017) 74:660–7. doi: 10.1001/jamaneurol.
2016.6179
72. Tateishi T, Yamasaki R, Tanaka M, Matsushita T, Kikuchi H, Isobe
N, et al. CSF chemokine alterations related to the clinical course
of amyotrophic lateral sclerosis. J Neuroimmunol. (2010) 222:76–81.
doi: 10.1016/j.jneuroim.2010.03.004
73. Rentzos M, Rombos A, Nikolaou C, Zoga M, Zouvelou V, Dimitrakopoulos
A, et al. Interleukin-15 and interleukin-12 are elevated in serum and
cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur Neurol.
(2010) 63:285–90. doi: 10.1159/000287582
74. Yang X, Gao L,WuX, Zhang Y, Zang D. Increased levels ofMIP-1 αin CSF and
serum of ALS. Acta Neurol Scand. (2015) 134:94–100. doi: 10.1111/ane.12513
75. Haraldsen G, Kvale D, Lien B, Farstad IN, Brandtzaeg P. Cytokine-regulated
expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and
vascular cell adhesion molecule-1 (VCAM-1) in human microvascular
endothelial cells. J Immunol. (1996) 156:2558–65. Available online at: http://
www.jimmunol.org/content/156/7/2558.long
76. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al.
Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. (2009)
10:310–23. doi: 10.3109/17482960802566824
77. Wirth AM, Khomenko A, Baldaranov D, Kobor I, Hsam O, Grimm T,
et al. Combinatory biomarker use of cortical thickness, MUNIX, and
ALSFRS-R at baseline and in longitudinal courses of individual patients with
amyotrophic lateral sclerosis. Front Neurol. (2018) 9:614. doi: 10.3389/fneur.
2018.00614
78. Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A,
et al. Prognosis for patients with amyotrophic lateral sclerosis: development
and validation of a personalised prediction model. Lancet Neurol. (2018)
17:423–33. doi: 10.1016/S1474-4422(18)30089-9
Conflict of Interest Statement:UB holds patents for clinical application of G-CSF
in ALS, Orphan Drug Status is granted for EU and US by EMA and FDA–all
within NeuroVision Pharma GmbH, Murnau, Germany.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2018 Johannesen, Budeus, Peters, Iberl, Meyer, Kammermaier, Wirkert,
Bruun, Samara, Schulte-Mattler, Herr, Schneider, Grassinger and Bogdahn. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Neurology | www.frontiersin.org 15 November 2018 | Volume 9 | Article 971
